In breast cancer cells, the increase in PKCα is associated with the switch to a hormone-independent phenotype [66,67] mediated by Notch-4 [68], also representing an indicator of hormone therapy failure [69,70], and by ErbB2 up-regulation, which determines a constitutive activation of the kinase, promoting cell invasion [71]. Here, PRKCA is linked to breast carcinoma.